# Efficacy, Acceptability and Safety of Event-driven HIV PrEP Using TAF/FTC in MSM in Thailand and France.

> **NCT05813964** · PHASE3 · RECRUITING · sponsor: **ANRS, Emerging Infectious Diseases** · enrollment: 524 (estimated)

## Conditions studied

- HIV/AIDS

## Interventions

- **DRUG:** TDF/FTC 300mg/200mg fixed-dose combination tablets
- **DRUG:** TAF/FTC 25mg/200mg fixed-dose combination tablets

## Key facts

- **NCT ID:** NCT05813964
- **Lead sponsor:** ANRS, Emerging Infectious Diseases
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-06-05
- **Primary completion:** 2026-10
- **Final completion:** 2027-05
- **Target enrollment:** 524 (ESTIMATED)
- **Last updated:** 2025-06-20

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05813964

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05813964, "Efficacy, Acceptability and Safety of Event-driven HIV PrEP Using TAF/FTC in MSM in Thailand and France.". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05813964. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*